SUMMARY Electrophysiologic studies were performed in 14 patients with atrioventricular nodal reentrant paroxysmal tachycardia (PSVT) before and after oral administration of 1.2-1.6 g quinidine sulfate over a 24-hour period (0.34.4 g every 6 hours). Studies were performed after 0.5-1 mg i.v. atropine before and after quinidine. All 14 patients had induction of sustained PSVT before quinidine, with or without atropine. After quinidine, 11 patients lost the ability to induce echoes or sustain PSVT, reflecting depression of the retrograde pathway with either absence of atrial echoes (six patients) or induction of nonsustained PSVT, with termination of echoes or PSVT occurring after QRS (block in retrograde pathway) (five patients). In only one of these 11 patients was sustained PSVT inducible after addition of atropine. All 11 were discharged on the same dose of quinidine. In three patients, quinidine was discontinued because of side effects. Follow-up in the remaining eight patients for 8 ± 2 months showed no recurrence of sustained PSVT. Three of the 14 patients had induction of sustained PSVT after quinidine. Ventricular paced cycle length producing ventriculoatrial block was 314 ± 7 msec (mean ± SEM) before and 392 ± 13 msec after quinidine (p < 0.01) in the 14 patients, suggesting depression of the retrograde pathway with quinidine.
In summary, quinidine inhibited induction of sustained atrioventricular nodal reentrant tachycardia with depression of the retrograde pathway. It is very effective in preventing recurrence of PSVT in most patients. DUAL PATHWAY atrioventricular (AV) nodal reentrant tachycardia, using a slow pathway for antegrade and a fast pathway for retrograde conduction, is a common arrhythmia.' 2 Propranolol, digitalis and verapamil inhibit arrhythmia attacks by depression of antegrade slow pathway conduction.A7 Procainamide inhibits arrhythmia attacks by depression of retrograde fast pathway conduction.8 Quinidine has also been recommended for treatment of paroxysmal supraventricular tachycardia (PSVT).9 Although data regarding the effects of quinidine on AV reentrant tachycardia are available,'0' 11 little information is available concerning the effects of quinidine on induction of AV nodal reentrant tachycar-dia.'2 We systematically examined the effects of oral quinidine sulfate and atropine on induction and maintenance of AV nodal reentrant tachycardia.
Methods
Criteria for inclusion in this study were (1) a history of electrocardiographically documented recurrent PSVT that required termination with i.v. medication; (2) (S,) . RA2, CS2, A2, H2 and V2 are right atrial, left atrial, low septal right atrial, His bundle, and ventricular responses to the extrastimulus (S2). Conduction intervals, refractory periods, and echo zone were measured and defined as previously described. 23 Critical AH or AV intervals are the shortest AH or AV intervals initiating PSVT.24 Diagnosis of AV nodal reentrant tachycardia was made using the previously described criteria." l 14 15, 24-29 Sustained tachycardia was defined when induced PSVT lasted longer than 2 minutes, requiring termination with electrical stimulation. Nonsustained tachycardia was defined when induced PSVT terminated spontaneously. The weak link of the reentrant circuit was defined as the site of increased refractoriness that prevented induction or maintenance of PSVT. The antegrade weak link was defined when echoes or PSVT were terminated with an atrial response not being followed by a QRS response. The retrograde weak link was defined when echoes or PSVT were terminated with a QRS response not being followed by an atrial response, or when an AV interval longer than the critical AV interval was achieved without inducing AV nodal reentrant atrial echoes or PSVT. (table 1) Sustained AV nodal reentrant tachycardia was inducible in all 14 patients during the control study (figs. 1-4). PSVT was inducible with incremental atrial pacing in every patient, in 12 patients with atrial extrastimulus testing (A1, A2) with definition of an echo zone (cases 2-11, 13 and 14); in two with incremental ventricular pacing (cases 10 and 13); and in one with ventricular extrastimulus testing with definition of an echo zone (case 10). Induction of PSVT with incremental atrial pacing or atrial extrastimulus testing was related to achievement of a critical AH (or AV) interval, reflecting antegrade block of a fast AV nodal pathway with resultant antegrade slow pathway conduction. Induction of PSVT with incremental ventricular pacing or ventricular extrastimulus testing reflected retrograde block of a slow AV nodal pathway as manifested by lack of VA delay. In all 14 patients, PSVT induction was also performed after administration of atropine, and all had induction of sustained PSVT after atropine.
Results

Induction of PSVT
After quinidine, sustained PSVT was inducible in only three patients, cases 1-3 ( fig. IC) . In cases 4-6, PSVT was no longer sustained after quinidine ( fig.  2C ). Termination of PSVT in these three patients occurred when the QRS complex was not followed by an atrial response, suggesting a retrograde weak link. In cases 7 and 8, only a single AV nodal reentrant echo was induced ( fig. 3C ). In both patients, the echo was terminated with QRS response not followed by an atrial response, suggesting a retrograde weak link. In cases 9-14, echoes or PSVT could not be induced after quinidine ( fig. 4C ). In these patients, AV intervals CIRCULATIONlonger than the cycle length that produced AV nodal block (301 ± 9 msec) during the control study. In cases 1-6, who had induction of sustained or nonsustained PSVT after quinidine, the cycle length of PSVT (389 ± 21 msec) was longer than the cycle length that produced AV block (329 ± 20 msec). Of the eight patients with induction of only a single AV nodal reentrant echo or without induction of echoes after quinidine, four (cases 7, 8, 10 and 14) had a cycle length of PSVT (before quinidine) longer than the cycle length that produced AV block after quinidine. These findings were consistent with the observation that the antegrade limb was not the limiting factor in the induction or sustaining of PSVT after quinidine.
Retrograde Properties (table 1, fig. 5) Retrograde properties of the fast pathway were evaluated by noting the longest ventricular paced cycle length that produced VA block. During the control study, the ventricular paced cycle lengths that Control produced VA block ranged from 280-360 msec (mean 314 ± 7 msec). After quinidine, the ventricular paced cycle length that produced VA block increased to 392 ± 13 msec (p < 0.01) (range 300-460 msec) (figs. lB and D, 2B and D, 3B and D, and 4B and D). In all 14 patients, the cycle length of PSVT (366 ± 9 msec) was longer than the cycle length that produced VA block (314 ± 7 msec) before quinidine ( figs. 1A and B,  2A and B, 3A and B, and 4A and B) . In cases 7-14, in whom the ability to induce PSVT was lost after quinidine, the cycle length that produced VA block after quinidine was longer, 413 ± 14 msec, than the cycle length of PSVT observed during the control study, 358 ± 8 msec (figs. 3A and D and 4A and D). In cases 4-6, with induction of nonsustained PSVT after quinidine, the cycle length that produced VA block was longer than the cycle of PSVT ( fig. 2A) . In cases 1-3, with induction of sustained PSVT after quinidine, the cycle length that produced VA block was shorter than the cycle length of PSVT ( fig. 1) .
The The paper speed is 100 mm/sec. i i 5u conduction system could be compared in cases 3, 4, 6, 8-11 and 13 before and after quinidine. The retrograde effective refractory period increased from < 253 i 15 before to 348 ± 23 msec after quinidine (p < 0.01). Although the site of conduction failure could not be determined, it could have reflected a failure in the fast pathway in some patients.
Follow-up Study
All 11 patients with loss of the ability to induce or sustain PSVT after quinidine were discharged on quinidine sulfate at a dose similar to that during electrophysiologic studies. In three patients (cases 4, 8 and 9), the drug was discontinued due to gastrointestinal side effects. The remaining eight patients have been followed for 8 ± 2 months, and have been free of symptomatic arrhythmia.
Discussion
In paroxysmal AV nodal reentrant tachycardia, the reentrant circuit consists of a slow AV nodal pathway, a fast pathway (most likely intranodal), a proximal connection (probably intranodal), and a distal connection. 29 The present study suggests that quinidine depresses retrograde fast pathway conduction and thus inhibits the ability to induce or sustain PSVT. These effects were substantiated by failure to induce AV nodal reentrant atrial echo with achievement of an AV interval longer than the critical AV interval during control study, loss of the ability to sustain PSVT with termination of PSVT occurring with a QRS not followed by an atrial response, and lengthening of the longest ventricular paced cycle length producing VA block. Quinidine also had no effect on the cycle length of PSVT. These findings are similar to previous observations with procainamide.' In contrast to procainamide, quinidine did not enhance antegrade slow pathway conduction. Quinidine might have depressed antegrade slow pathway conduction in some patients, but antegrade slow pathway conduction did not appear to be a limiting factor in inducting or sustaining PSVT after quinidine. Nevertheless, the previous procainamide study was performed with i.v. drug administration and the present study of quinidine was performed with oral drug administration. A more prominent effect of hypotension or vagolysis after i.v. medication may have accounted for the difference in antegrade slow pathway properties between these two drugs.
The conduction properties of both antegrade slow and retrograde fast pathway are autonomically mediated, which may vary from day to day."' 37 Variation in the conduction properties of either the antegrade slow or the retrograde fast pathway may render oral pharmacologic study less valid. Therefore, we administered atropine to overcome this possibility. In the 11 patients with loss of the ability to induce or sustain PSVT after quinidine, sustained PSVT occurred in only one patient after administration of atropine, which enhanced retrograde fast pathway conduction.
Thus, the depressed effect of quinidine on retrograde fast pathway conduction was maintained even after elimination of vagal influence, suggesting that this effect was not subject to diurnal variation of retrograde fast pathway conduction properties. The shortterm follow-up in this study further supported this observation.
In conclusion, quinidine depresses retrograde fast pathway conduction and thus inhibits induction or sustenance of PSVT in patients with AV nodal reentrant tachycardia. Oral quinidine does not enhance antegrade slow pathway conduction and, therefore, does not potentiate PSVT. It is a useful drug in preventing recurrence of PSVT.
